CaseVuNo products in the cart.
Chronic Lymphocytic Leukemia (CLL) Panel Information
The HemeScreen® CLL Panel offerings are research use only assays that detect somatic mutations in targets of interest related to chronic lymphocytic leukemia (CLL). This reagent set is specifically designed to screen for mutations using High Resolution Melt Analysis in CXCR4, MYD88, NOTCH1, and SF3B1 genes. This reagent set is designed for use by suitably trained personnel testing DNA extracted from whole blood or bone marrow samples using a RT-PCR-based method, or High Resolution Melt (HRM) Analysis.
Technical Overview IFU SDS Shop
Development Of The HemeScreen CLL Panel
Precipio’s own clinical hematopathology laboratory developed the HemeScreen CLL panel to address the issues of turn-around time and accurate, comprehensive molecular testing for gene mutations associated with chronic lymphocytic leukemia (CLL). By taking a panel approach to gene mutation detection for suspected CLL cases, Precipio’s clinical hematopathology lab is able to identify incidence of single mutations, mutation changes, and co-expression in a single assay run on one platform. This provides our lab with a more efficient testing workflow and enables rapid turn around time.
HemeScreen Chronic Lymphocytic Leukemia (CLL) Assay Configurations
The HemeScreen CLL panel comes pre-plated with optimized primers and embedded mutant, NTC, and wild type controls for driver mutation genes of interest for CLL. This simplifies lab inventory management by providing a complete molecular assay without tracking multiple SKUs of single gene testing assays that require separate control kits.
3-sample pre-plated, and vialed free flow configurations are available for the CLL panel. Custom configurations are also possible.
HemeScreen Workflow
Sample preparation is based off of standard DNA extraction techniques. Most HRM-enabled RT-PCR instruments can run the HemeScreen CLL assay after DNA samples are plated. Data is captured in real time and melt curves can be analyzed to determine the mutation status of CXCR4, MYD88, NOTCH1, and SF3B1 genes.